Investing in the Future of Human Longevity
A Hong Kong-based venture capital fund backing world-class startups at the frontier of gerontology, anti-aging science, and healthspan innovation — accelerating breakthroughs that help people live longer, healthier lives.
AGVC is a venture capital fund headquartered in Hong Kong, purpose-built to identify and accelerate the most promising startups operating at the intersection of aging science, longevity medicine, and healthspan technology.
We believe the next great wave of innovation will be defined by our ability to understand, slow, and reverse the biological processes of aging. Gerontology is transitioning from academic inquiry to investable, scalable commercial opportunity — and AGVC is positioned to back the companies that will lead this transformation.
With Hong Kong as our base, we leverage Asia's unique advantages — world-class research institutions, deep manufacturing ecosystems, and access to the world's largest aging population — while sourcing deals globally from Silicon Valley to Singapore to Tel Aviv.
The global population aged 60+ will double to 2.1 billion by 2050. We are at an inflection point — biological aging is becoming addressable. AGVC backs the companies making that possible.
Cellular reprogramming, senolytics, and molecular interventions that extend healthy human lifespan.
Neurotechnology and therapeutics targeting age-related cognitive decline, neurodegeneration, and brain resilience.
Novel drugs, biologics, and regenerative medicine targeting the hallmarks of aging.
Biomarker discovery, epigenetic clocks, and precision diagnostics for biological age measurement.
AI-accelerated drug discovery and computational biology applied to aging research.
Digital health, preventive care, and behavior-change platforms maximizing quality of life across decades.
We invest at the frontier where basic longevity research is maturing into viable therapeutic and technology platforms.
Asia is home to the world's largest aging demographic and healthcare systems primed for longevity innovation.
We help portfolio companies navigate cross-border regulatory, clinical, and market pathways for maximum impact.
We invest across the full healthspan and longevity stack — from deep biotech to digital health platforms.
Our team combines decades of venture capital, biomedical research, and operational experience to support founders building the longevity economy.
AGVC is supported by a Scientific Advisory Board comprising leading researchers in gerontology, molecular biology, and longevity medicine from top institutions worldwide. Details to be announced.
Building a company in the longevity, healthspan, or anti-aging space? We'd love to hear from you. Tell us about your vision.